Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein

McCabe, Victoria J.; Tarpey, Ian; Spibey, N.

doi:10.1016/s0264-410x(02)00186-x

Cited by 34 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, increased replication of vector pCF-FCV24-U3 in two cases provided FCV disease protection. The induction of mucosal immunity is an advantage of FFV-based vectors compared to other viral vaccine vectors applied with variable effects in cats (20,(38)(39)(40).…”

Section: Discussionmentioning

confidence: 99%

Application of Chimeric Feline Foamy Virus-Based Retroviral Vectors for the Induction of Antiviral Immunity in Cats

Schwantes

Truyen

Weikel

et al. 2003

J Virol

View full text Add to dashboard Cite

In order to define the potential and applicability of replication-competent foamy virus-based vaccine vectors, recombinant feline foamy virus (FFV) vectors encoding defined segments of the feline calicivirus (FCV) capsid protein E domain were constructed. In cell cultures, these FFV-FCV vectors efficiently transduced and expressed a hybrid fusion protein consisting of the essential FFV Bet protein and the attached FCV E domains. The stability of the vectors in vitro was inversely correlated to the size of the heterologous insert. The deletion of a part of the FFV U3 sequence in these FFV-FCV vectors did not interfere with replication and titer in cell cultures but increased the genetic stability of the hybrid vectors. Selected chimeric vectors were injected into immunocompetent cats and persisted in the transduced host concomitant with a strong and specific humoral immune response against vector components. In a substantial number of cats, antibodies directed against the FCV E domain were induced by the FFV-FCV vectors, but no FCV-neutralizing activities were detectable in vitro. When the vaccinated cats were challenged with a high-titer FCV dose, sterile immunity was not induced by any of the hybrid FFV-FCV vectors. However, the FFV-FCV vector with a truncated U3 region of the long terminal repeat promoter significantly reduced the duration of FCV shedding after challenge and suppressed the appearance of FCV-specific ulcers. Possible mechanisms contributing to the partial protection will be discussed.The great success of applied virology during the last century has been mainly due to the development and application of efficient and safe antiviral vaccines. These prevent virus-mediated disease or spread of the infectious agent and have even resulted in the eradication of poxvirus (reviewed in reference 7). These achievements are on one hand based on the injection of defined virus-derived proteins, as in the case of the hepatitis B virus vaccine or inactivated viruses, which are both capable of inducing a stable and broadly reactive humoral immunity. Alternatively, attenuated, apathogenic virus variants and/or related viruses inducing a stable cross-protection are used. Modified live virus vaccines have the great advantage of mimicking the natural route and mode of virus replication, inducing not only a humoral, mainly immunoglobulin G (IgG)-mediated immunity, but also stimulating the cell-mediated and/or mucosal arm of the adaptive immune response (7). Although these strategies have been efficient in controlling various viruses pathogenic to humans and livestock animals, vaccines against some virus infections are presently either not available or display only a limited degree of protection (23).Over the last several years, novel vaccination strategies have been developed based on recombinant, chimeric viruses used to deliver and efficiently express heterologous vaccine antigens in the recipient (28). These novel strategies include not only prophylactic preexposure vaccination but also therapeutic postexposure im...

show abstract

Section: Discussionmentioning

confidence: 99%

Application of Chimeric Feline Foamy Virus-Based Retroviral Vectors for the Induction of Antiviral Immunity in Cats

Schwantes

Truyen

Weikel

et al. 2003

J Virol

View full text Add to dashboard Cite

show abstract

“…There are some published reports of novel vaccine technologies including DNA vaccination [100], myxoma recombinants [66,67], and herpesvirus recombinants [118] for FCV. Such vaccines could offer several potential advantages over those based on conventional technologies including inability to induce FCV infection, and induction of a local mucosal immune response.…”

Section: Vaccinesmentioning

confidence: 99%

Feline calicivirus

et al. 2007

View full text Add to dashboard Cite

-Feline calicivirus (FCV) is an important and highly prevalent pathogen of cats. It belongs to the family Caliciviridae which includes other significant pathogens of man and animals. As an RNA virus, high polymerase error rates convey upon FCV a high genome plasticity, and allow the virus to respond rapidly to environmental selection pressures. This makes the virus very adaptable and has important implications for clinical disease and its control. Being genetically diverse, FCV is associated with a range of clinical syndromes from inapparent infections to relatively mild oral and upper respiratory tract disease with or without acute lameness. More recently, highly virulent forms of the virus have emerged associated with a systemic infection that is frequently fatal. A proportion of FCV infected cats that recover from acute disease, remain persistently infected. In such cats, virus evolution is believed to help the virus to evade the host immune response. Such longterm carriers may only represent a minority of the feline population but are likely to be crucial to the epidemiology of the virus. Vaccination against FCV has been available for many years and has effectively reduced the incidence of clinical disease. However, the vaccines do not prevent infection and vaccinated cats can still become persistently infected. In addition, FCV strain variability means that not all strains are protected against equally. Much progress has been made in understanding the biology and pathogenesis of this important feline virus. Challenges for the future will necessarily focus on how to control the variability of this virus particularly in relation to emerging virulent strains and vaccination.

show abstract

“…To date, MV has been shown not to be able to infect any other vertebrate family besides lagomorphs in vivo; including day old mice [1], cats [63], and humans [40]. However, reports have indicated that MV can infect non-lagomorph cells in vitro; including squirrels, guinea pigs and primate kidney cells [16,97].…”

Section: Prevention Control and Vaccinationmentioning

confidence: 99%

Myxoma virus in the European rabbit: interactions between the virus and its susceptible host

2007

View full text Add to dashboard Cite

-Myxoma virus (MV) is a poxvirus that evolved inSylvilagus lagomorphs, and is the causative agent of myxomatosis in European rabbits (Oryctolagus cuniculus). This virus is not a natural pathogen of O. cuniculus, yet is able to subvert the host rabbit immune system defenses and cause a highly lethal systemic infection. The interaction of MV proteins and the rabbit immune system has been an ideal model to help elucidate host/poxvirus interactions, and has led to a greater understanding of how other poxvirus pathogens are able to cause disease in their respective hosts. This review will examine how MV causes myxomatosis, by examining a selection of the identified immunomodulatory proteins that this virus expresses to subvert the immune and inflammatory pathways of infected rabbit hosts. myxoma virus / immunomodulation / poxvirus / Oryctolagus cuniculus

show abstract

Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein

Cited by 34 publications

References 33 publications

Application of Chimeric Feline Foamy Virus-Based Retroviral Vectors for the Induction of Antiviral Immunity in Cats

Application of Chimeric Feline Foamy Virus-Based Retroviral Vectors for the Induction of Antiviral Immunity in Cats

Feline calicivirus

Myxoma virus in the European rabbit: interactions between the virus and its susceptible host

Contact Info

Product

Resources

About